Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: A case-control study

作者：Laharie David; Seneschal Julien; Schaeverbeke Thierry; Doutre Marie Sylvie; Longy Boursier Maite; Pellegrin Jean Luc; Chabrun Edouard; Villars Sandrine; Zerbib Frank; de Ledinghen Victor^*

来源：Journal of Hepatology, 2010, 53(6): 1035-1040.

DOI：10.1016/j.jhep.2010.04.043

• Methotrexate
• Liver fibrosis
• FibroScan
• Transient elastography
• FibroTest
• Cirrhosis
• Psoriasis
• Crohn s disease
• Rheumatoid arthritis

Background & Alms Although methotrexate (MIX) is used in the effective treatment of inflammatory disorders its use is hampered by the risk of liver fibrosis Non-invasive methods for the diagnosis of liver fibrosis such as transient elastography (FibroScan) and FibroTest could be useful for monitoring MIX liver toxicity The aim of this case control study was to determine factors associated with liver fibrosis in a large cohort of patients requiring MTX
Methods Consecutive adults with various benign inflammatory diseases were prospectively assessed using FibroScan and FibroTest when they were treated with MIX (cases) or before beginning treatment (controls)
Results Among 518 included patients 44 patients (85%) had FibroScan and/or FibroTest results suggesting severe liver fibrosis In a multivariate analysis factors associated with abnormal markers of liver fibrosis were the body mass Index >28 kg/m(2) and high alcohol consumption Neither long MIX duration nor cumulative doses were associated with elevated FibroScan or FibroTest results
Conclusions Severe liver fibrosis is a rare event in patients treated with MTX and is probably unrelated to the total dose Patients with other risk factors for li

• 出版日期2010-12
• 单位河南工业大学